{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:14:20Z","timestamp":1773270860699,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,11]]},"DOI":"10.7759\/cureus.105022","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:06:21Z","timestamp":1773216381000},"source":"Crossref","is-referenced-by-count":0,"title":["Fibrodysplasia Ossificans Progressiva: A Case Report From the UAE"],"prefix":"10.7759","author":[{"given":"Tabarak M","family":"Al Karam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batool M","family":"Alkaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafah Z","family":"Basil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safwan A","family":"Alzaghal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalla","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153792","article-title":"Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1","volume":"132","author":"Aykul S","year":"2022","unstructured":"Aykul S, Huang L, Wang L, et al.. Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1. J Clin Invest. 2022, 132:153792. 10.1172\/JCI153792","journal-title":"J Clin Invest"},{"key":"ref2","article-title":"Fibrodysplasia ossificans progressiva","author":"Akesson LS","year":"2024","unstructured":"Akesson LS, Savarirayan R. Fibrodysplasia ossificans progressiva. GeneReviews\u00ae [Internet]. Adam MP, Bick S, Mirzaa GM, et al. (ed): University of Washington, Seattle (WA); 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/BF02276711","article-title":"Fibrodysplasia ossificans progressiva: still turning into wood after 300 years?","volume":"154","author":"Buyse G","year":"1995","unstructured":"Buyse G, Silberstein J, Goemans N, Casaer P. Fibrodysplasia ossificans progressiva: still turning into wood after 300 years?. Eur J Pediatr. 1995, 154:694-9. 10.1007\/BF02276711","journal-title":"Eur J Pediatr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115274","article-title":"Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry","volume":"134","author":"Pignolo RJ","year":"2020","unstructured":"Pignolo RJ, Cheung K, Kile S, et al.. Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry. Bone. 2020, 134:115274. 10.1016\/j.bone.2020.115274","journal-title":"Bone"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-019-2297-z","article-title":"Fibrodysplasia ossificans progressiva (stone man syndrome): a case report","volume":"13","author":"Shah ZA","year":"2019","unstructured":"Shah ZA, Rausch S, Arif U, El Yafawi B. Fibrodysplasia ossificans progressiva (stone man syndrome): a case report. J Med Case Rep. 2019, 13:364. 10.1186\/s13256-019-2297-z","journal-title":"J Med Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s44162-025-00144-4","article-title":"Fibrodysplasia ossificans progressiva: from clinical complexity to therapeutic opportunity","volume":"5","author":"Chakraborty A","year":"2026","unstructured":"Chakraborty A, Chakrabarty US, Mal M, et al.. Fibrodysplasia ossificans progressiva: from clinical complexity to therapeutic opportunity. J Rare Dis. 2026, 5:1. 10.1007\/s44162-025-00144-4","journal-title":"J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01983-2","article-title":"Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization","volume":"16","author":"Pignolo RJ","year":"2021","unstructured":"Pignolo RJ, Hsiao EC, Baujat G, Lapidus D, Sherman A, Kaplan FS. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021, 16:350. 10.1186\/s13023-021-01983-2","journal-title":"Orphanet J Rare Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20868","article-title":"Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1","volume":"30","author":"Kaplan FS","year":"2009","unstructured":"Kaplan FS, Xu M, Seemann P, et al.. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009, 30:379-90. 10.1002\/humu.20868","journal-title":"Hum Mutat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.09.014","article-title":"Clinical staging of fibrodysplasia ossificans progressiva (FOP)","volume":"109","author":"Pignolo RJ","year":"2018","unstructured":"Pignolo RJ, Kaplan FS. Clinical staging of fibrodysplasia ossificans progressiva (FOP). Bone. 2018, 109:111-4. 10.1016\/j.bone.2017.09.014","journal-title":"Bone"},{"key":"ref10","article-title":"The medical management of fibrodysplasia ossificans progressiva: current treatment considerations","volume":"3","author":"Kaplan FS","year":"2024","unstructured":"Kaplan FS. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2024, 3:1-159.","journal-title":"Proc Intl Clin Council FOP"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2422548","article-title":"Current and emerging treatment modalities for fibrodysplasia ossificans progressiva","volume":"25","author":"Gen\u00e7el D","year":"2024","unstructured":"Gen\u00e7el D, Erbil NN, Demiry\u00fcrek \u015e, Demiry\u00fcrek AT. Current and emerging treatment modalities for fibrodysplasia ossificans progressiva. Expert Opin Pharmacother. 2024, 25:2225-34. 10.1080\/14656566.2024.2422548","journal-title":"Expert Opin Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439593-fibrodysplasia-ossificans-progressiva-a-case-report-from-the-uae","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:06:22Z","timestamp":1773216382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439593-fibrodysplasia-ossificans-progressiva-a-case-report-from-the-uae"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.105022","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}